Kurin, Inc. Provides Update on Litigation Activity

Kurin, Inc., the inventor and manufacturer of the Kurin® blood culture collection sets, provides an update to the most recent moves by Magnolia Medical Technologies. This week, Magnolia filed a motion in the US District Court of Delaware for a permanent injunction, hoping to take Kurin off the market.

“We are disappointed, but not surprised by their attempt to create a monopoly and deprive customers of the ability to choose the most appropriate solution for them,” said Bob Rogers, CEO and Inventor of Kurin. “We will vigorously defend access to the best solution to the contaminated blood culture problem. Our experience over the past few years shows that hospitals have rejected Magnolia’s Steripath product because it is unnecessarily complex and difficult to use.  Kurin’s innovation in developing a smaller, simpler device is a demonstration of how the intellectual property system should work in America and explains why we are the market leader. We will not be bullied by a venture-backed company who continues to spend their millions on litigation in hopes of creating a monopoly. We are heartened by the support of Kurin customers, and have been told they too are upset at Magnolia’s attempts to use the legal system to reduce choice and negatively impact clinical outcomes.”

Kurin’s revolutionary approach to the contaminated blood culture problem is an elegantly simple, intuitive design that requires no additional user steps. Kurin passively sidelines potential contaminants during blood culture collection. Kurin is a simply better and more sustainable approach over conventional mechanical diversion. Contaminated blood cultures are a significant problem, as roughly one-third of the positive results are wrong, exposing these patients to unnecessary antibiotics, extending hospital stays and impacting larger community health issues, such as antimicrobial resistance and the life-threatening infections caused by C. diff.

About Kurin, Inc.

Kurin Inc., a certified Minority Business Enterprise (MBE), is focused on the design, development, manufacture, marketing, and sale of products that help healthcare providers reduce contaminated blood cultures. San Diego-based Kurin has received FDA 510(k) market clearance. For more information, visit the website at www.kurin.com.